Novartis Delivers Strong Second Quarter and 50 Million CureVac Vaccines

[cafead]

via Novartis reported its second-quarter financials today, with net sales growing 15% to $12.956 billion (U.S.), hitting $25.367 billion for the half-year mark. The company also reported on its COVID-19 vaccine production with CureVac and some changes to its pipeline.

article source